ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).
BACKGROUND
ABO blood group has been associated with risk of cancers of the pancreas, stomach, ovary, kidney, and skin, but has not been evaluated in relation to risk of aggressive prostate cancer.


METHODS
We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). Unconditional logistic regression was used to calculate age and study-adjusted odds ratios and 95% confidence intervals for the association between blood type, genotype, and risk of aggressive prostate cancer (Gleason score ≥8 or locally advanced/metastatic disease (stage T3/T4/N1/M1).


RESULTS
We found no association between ABO blood type and risk of aggressive prostate cancer (Type A: OR = 0.97, 95%CI = 0.87-1.08; Type B: OR = 0.92, 95%CI =n0.77-1.09; Type AB: OR = 1.25, 95%CI = 0.98-1.59, compared to Type O, respectively). Similarly, there was no association between "dose" of A or B alleles and aggressive prostate cancer risk.


CONCLUSIONS
ABO blood type was not associated with risk of aggressive prostate cancer.
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Sarah C
SC
Markt
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Irene M
IM
Shui
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Robert H
RH
Unger
Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey.
Yuksel
Y
Urun
Department of Radiation Oncology, Johns Hopkins Medicine, Baltimore, Maryland.
Christine D
CD
Berg
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Amanda
A
Black
International Agency for Research on Cancer, Lyon, France.
Paul
P
Brennan
National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.|Departments of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands.|Departments of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, UK.|Departments of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
H Bas
HB
Bueno-de-Mesquita
Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
Susan M
SM
Gapstur
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Edward
E
Giovannucci
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Christopher
C
Haiman
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Brian
B
Henderson
International Agency for Research on Cancer, Lyon, France.
Robert N
RN
Hoover
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
David J
DJ
Hunter
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Timothy J
TJ
Key
School of Clinical Medicine, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK.
Kay-Tee
KT
Khaw
Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Federico
F
Canzian
Public Health Division of Gipuzkoa, BIODonostia Research Institute, Basque Health Department, Spain.|CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Nerea
N
Larranga
Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Loic
L
Le Marchand
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jing
J
Ma
HuGeF Foundation Molecular and Genetic Epidemiology Unit, Torino, Italy.
Alessio
A
Naccarati
Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK.
Afshan
A
Siddiq
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Meir J
MJ
Stampfer
Department of Surgery and Perioperative sciences, Urology and Andrology, Ume, å, University, Sweden.
Par
P
Stattin
Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Victoria L
VL
Stevens
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Daniel O
DO
Stram
Danish Cancer Society Research Center, Copenhagen, Denmark.
Anne
A
Tjønneland
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ruth C
RC
Travis
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece.|Hellenic Health Foundation, Athens, Greece.
Dimitrios
D
Trichopoulos
International Agency for Research on Cancer, Lyon, France.
Regina G
RG
Ziegler
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Sara
S
Lindstrom
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Peter
P
Kraft
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.|Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Lorelei A
LA
Mucci
Department of Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Toni K
TK
Choueiri
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Kathryn M
KM
Wilson
D000017:ABO Blood-Group System / Q000235:genetics*; D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000483:Alleles; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology
D000017:ABO Blood-Group System
ABO; blood type; genetic epidemiology; prostate cancer